Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT05665595 2025-10-15

KEYVIBE-010

Phase 3 Completed

1,594 enrolled 12 charts

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04341064 2025-10-14

SHINE

Phase 3 Completed

2,223 enrolled

Dermatologic

Skin Neoplasms

NCT02752074 2025-08-24

A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Phase 3 Completed

706 enrolled 17 charts

Dermatologic

Melanoma

NCT02908672 2025-07-20

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Phase 3 Completed

514 enrolled 25 charts 2 FDA

Dermatologic

Melanoma

NCT01844505 2025-05-21

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Phase 3 Completed

945 enrolled 19 charts

Dermatologic

Melanoma

NCT02166788 2025-05-09

EAGLE FM

Phase 3 Completed

634 enrolled

Dermatologic

Melanoma

NCT03551626 2025-04-29

COMBI-APlus

Phase 3 Completed

552 enrolled 12 charts

Dermatologic

Fever, Melanoma

NCT02388906 2025-04-24

CheckMate 238

Phase 3 Completed

906 enrolled 16 charts 1 FDA

Dermatologic

Melanoma

NCT00472459 2025-04-18

Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer

Phase 3 Completed

82 enrolled 20 charts

Dermatologic

Bowen's Disease, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Warts, Keratosis, Actinic

NCT03635983 2025-04-01

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Phase 3 Completed

783 enrolled 24 charts

Dermatologic

Melanoma

NCT03172299 2025-03-24

PROTECT

Phase 3 Completed

57 enrolled

Dermatologic

Uveal Melanoma

NCT02549352 2025-03-13

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Phase 3 Completed

391 enrolled 16 charts

Dermatologic

Keratosis, Actinic

NCT01541553 2025-03-10

A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp

Phase 3 Completed

367 enrolled 10 charts

Dermatologic

Keratosis, Actinic

NCT02278887 2025-03-10

TIL

Phase 3 Completed

168 enrolled

Dermatologic

Melanoma

NCT02361216 2025-03-10

Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest

Phase 3 Completed

729 enrolled 14 charts

Dermatologic

Keratosis, Actinic

NCT02547233 2025-03-10

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up

Phase 3 Completed

437 enrolled 15 charts

Dermatologic

Keratosis, Actinic

NCT02547363 2025-03-10

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Phase 3 Completed

373 enrolled 13 charts

Dermatologic

Keratosis, Actinic

NCT02549339 2025-03-10

Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up

Phase 3 Completed

383 enrolled 16 charts

Dermatologic

Keratosis, Actinic

NCT01787383 2025-02-24

A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities

Phase 3 Completed

200 enrolled 16 charts

Dermatologic

Keratosis, Actinic

NCT01748448 2025-02-17

ViDMe

Phase 3 Completed

436 enrolled 16 charts

Dermatologic

Melanoma, Cutaneous Malignant

NCT02993315 2025-02-03

MIND-DC

Phase 3 Completed

148 enrolled

Dermatologic

Melanoma

NCT01871727 2024-11-13

A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma

Phase 3 Completed

112 enrolled 40 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT03430297 2024-09-19

JS001

Phase 3 Completed

256 enrolled

Dermatologic

Melanoma

NCT00472043 2024-08-06

PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma

Phase 3 Completed

66 enrolled 15 charts

Dermatologic

Carcinoma, Basal Cell

NCT03703310 2024-07-03

Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)

Phase 3 Completed

174 enrolled 23 charts

Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT01728805 2024-04-25

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Phase 3 Completed

372 enrolled 14 charts 1 FDA

DermatologicLymphoid

Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT05231044 2024-04-19

A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp

Phase 3 Completed

108 enrolled

Dermatologic

Skin Diseases, Keratosis, Actinic

NCT04552327 2024-03-05

KOHDIAK

Phase 3 Completed

631 enrolled

Dermatologic

Keratosis, Actinic

NCT01785316 2024-01-26

SCANDIUM

Phase 3 Completed

93 enrolled

Dermatologic

Melanoma, Uveal Neoplasms

NCT05279131 2024-01-23

A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis

Phase 3 Completed

105 enrolled 26 charts

Dermatologic

Keratosis, Actinic

NCT02678572 2023-12-21

FOCUS

Phase 3 Completed

102 enrolled 1 FDA

Dermatologic

Uveal Melanoma

NCT02124733 2023-10-10

Protocols for Painless Photodynamic Therapy (PDT) of Actinic Keratoses

Phase 3 Completed

23 enrolled

Dermatologic

Keratosis, Actinic

NCT01682083 2023-08-30

COMBI-AD

Phase 3 Completed

870 enrolled 13 charts 1 FDA

Dermatologic

Melanoma, Neoplasms

NCT01966120 2023-07-28

Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)

Phase 3 Completed

87 enrolled 21 charts

Dermatologic

Keratosis, Actinic

NCT00304239 2023-07-03

Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp

Phase 3 Completed

131 enrolled 9 charts

Dermatologic

Keratosis, Actinic

NCT00003027 2023-06-22

Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma

Phase 3 Completed

482 enrolled

Dermatologic

Melanoma

NCT00003444 2023-06-22

Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin

Phase 3 Completed

167 enrolled

Dermatologic

Melanoma

NCT01359956 2023-04-11

SICOG 0109

Phase 3 Completed

269 enrolled 12 charts

Dermatologic

Melanoma

NCT05078827 2023-03-14

Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis

Phase 3 Completed

458 enrolled

Dermatologic

Keratosis, Actinic

NCT03294330 2023-01-12

SPYX

Phase 3 Completed

35 enrolled 9 charts

BreastDermatologic

Breast Neoplasms, Melanoma

NCT02997553 2023-01-09

GASVERT

Phase 3 Completed

744 enrolled

BreastDermatologicGastrointestinalGynecologicHead & Neck

Anus Neoplasms, Breast Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT00473343 2023-01-05

Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma

Phase 3 Completed

102 enrolled 13 charts

Dermatologic

Carcinoma, Basal Cell

NCT01720407 2022-12-06

ImiReduc

Phase 3 Completed

259 enrolled

Dermatologic

Lentigo Maligna Melanoma (Head or Neck)

Clinical Trials

COLUMBUS

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

LEAP-003

TirbAKare

LEAP-003

CERTICOEUR

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

KEYVIBE-010

SHINE

A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

EAGLE FM

COMBI-APlus

CheckMate 238

Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

PROTECT

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp

TIL

Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up

A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities

ViDMe

MIND-DC

A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma

JS001

PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma

Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp

KOHDIAK

SCANDIUM

A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis

FOCUS

Protocols for Painless Photodynamic Therapy (PDT) of Actinic Keratoses

COMBI-AD

Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)

Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp

Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma

Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin

SICOG 0109

Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis

SPYX

GASVERT

Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma

ImiReduc